Results 11 to 20 of about 2,722 (180)

Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. [PDF]

Arthritis Care Res (Hoboken), 2012
AbstractObjectiveJuvenile localized scleroderma (LS) is a chronic inflammatory skin disorder associated with substantial morbidity and disability. Although a wide range of therapeutic strategies has been reported in the literature, a lack of agreement on treatment specifics and accepted methods for clinical assessment has made it difficult to compare ...
Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.   +24 more
europepmc   +6 more sources

Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature [PDF]

Clinical Case Reports
Juvenile scleroderma (JS) is a rare chronic connective tissue disorder characterized by progressive fibrosis of the skin and soft tissues with/without internal organ involvements.
Aye Miremarati, Kosar Babaeian Roshani, Manijeh Tabrizi, Fatemeh Tahghighi Sharabian, Seyyedeh Azade Hoseini Nouri   +4 more
doaj   +3 more sources

Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma [PDF]

Pediatric Rheumatology Online Journal, 2018
Objectives To assess reliability of the two indexes of Localized Scleroderma Cutaneous Assessment Tool (LoSCAT), the modified Localized Scleroderma Skin Severity Index (mLoSSI) and the Localized Scleroderma Skin Damage Index (LoSDI), when applied by ...
Anna Agazzi, Gloria Fadanelli, Fabio Vittadello, Francesco Zulian, Giorgia Martini   +4 more
doaj   +2 more sources

Juvenile localized scleroderma with port wine stain: Coincidental or possible common pathogenetic association

Indian Journal of Dermatology, 2015
Port wine stain and juvenile localized scleroderma are two different dermatoses usually encountered in pediatric age group. Up to now, there are reports of morphea patients initially diagnosed and treated as port wine stain.
Seval Dogruk Kacar, Pinar Ozuguz, Serap Polat, Emre Kacar, Onur Polat, Cigdem Tokyol   +5 more
doaj   +2 more sources

Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers’ perspectives [PDF]

Pediatric Rheumatology Online Journal, 2023
Background Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare pediatric conditions often associated with severe morbidities. Delays in diagnosis are common, increasing the risk for permanent damage and worse outcomes.
Leigh A. Stubbs, Andrew M. Ferry, Danielle Guffey, Christina Loccke, Erin Moriarty Wade, Pamela Pour, Kaveh Ardalan, Peter Chira, Ingrid M. Ganske, Daniel Glaser, Gloria Higgins, Nadia Luca, Katharine F. Moore, Vidya Sivaraman, Katie Stewart, Natalia Vasquez-Canizares, Raegan D. Hunt, Renata S. Maricevich, Kathryn S. Torok, Suzanne C. Li, Childhood Arthritis, Rheumatology Research Alliance (CARRA) Scleroderma Workgroup   +20 more
doaj   +3 more sources

Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study [PDF]

Pediatric Rheumatology Online Journal, 2019
Background We designed and initiated a pilot comparative effectiveness study for juvenile localized scleroderma (jLS), for which there is limited evidence on best therapy.
Suzanne C. Li, Robert C. Fuhlbrigge, Ronald M. Laxer, Elena Pope, Maria F. Ibarra, Katie Stewart, Thomas Mason, Mara L. Becker, Sandy Hong, Fatma Dedeoglu, Kathryn S. Torok, C. Egla Rabinovich, Polly J. Ferguson, Marilynn Punaro, Brian M. Feldman, Tracy Andrews, Gloria C. Higgins, For the CARRA Registry Investigators   +17 more
doaj   +2 more sources

JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review [PDF]

Pediatric Rheumatology Online Journal
Background Juvenile localized scleroderma (JLS) is a chronic autoimmune and fibrosing disease that can cause significant damage and impairments. Currently, management of JLS is challenging due to the paucity of antifibrotic drugs. In patients with severe
Rongjun Zheng, Lixia Zou, Suzanne C. Li, Meiping Lu   +3 more
doaj   +2 more sources

Revealing Microvascular Involvement in Pediatric Localized Scleroderma Through Nailfold Capillaroscopy [PDF]

Children
Background/Objectives: Juvenile localized scleroderma (jLoS) is a chronic inflammatory disorder with skin and subcutaneous tissue involvement. Microvascular alterations are thought to contribute to its pathogenesis.
Sema Nur Taşkın, Şeyda Doğantan, Esra Esen, Sümeyra Özdemir Çiçek, Ayşenur Paç Kısaarslan, Muammer Hakan Poyrazoğlu   +5 more
doaj   +2 more sources

Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. [PDF]

Arthritis Care Res (Hoboken), 2017
ObjectiveLocalized scleroderma can negatively affect children's quality of life (QoL), but predictors of impact have not been well described. We sought to identify predictors of QoL impact in juvenile localized scleroderma patients.MethodsWe analyzed longitudinal data from a single‐center cohort of juvenile localized scleroderma patients, using ...
Ardalan K, Zigler CK, Torok KS.
europepmc   +4 more sources

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review [PDF]

Pharmaceuticals
Background: Juvenile scleroderma (JS) comprises a group of rare chronic autoimmune and fibrosing disorders in children, primarily presenting as juvenile localized scleroderma (jLS) or juvenile systemic sclerosis (jSS). While jLS predominantly affects the
Chiara Sassetti, Claudia Borrelli, Martha Mazuy, Cristina Guerriero, Donato Rigante, Susanna Esposito   +5 more
doaj   +2 more sources